Neogene Therapeutics, Inc.: Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
Approval Marks Neogene's Transition to a Clinical-Stage Company NT-125 is a unique, multi-specific TCR therapy targeting neoantigens specific to each individual cancer patient Neogene Therapeutics
Carsten Linnemann Raphael Rousseau Kostenloser Wertpapierhandel Chan Lee Sheryl Seapy Neogene Therapeutics Inc
Source: finanznachrichten.de